NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

• NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

A phase 1/2a, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).

Biological: LAVA-051

Sponsor

Lava Therapeutics

---

ClinicalTrials.gov Identifier: NCT04887259

Official Title: A Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of LAVA-051 in Patients With Relapsed or Refractory CLL, MM, or AML

ClinicalTrials.gov Identifier:

First Posted : May 14, 2021

Click here to see details on ClinicalTrials.gov

---

Biological: LAVA-051

Anti-CD1d/Vdelta2 Gamma Delta T-cell Engaging Bispecific Antibody LAVA-051 (Code C180683)

Anti-CD1d/Anti-Vdelta2 Gamma Delta Bispecific T-cell Engager Antibody LAVA-051

Anti-CD1d/Vdelta2 Gamma Delta T-cell Engaging Bispecific Antibody LAVA-051

bsTCE Antibody LAVA-051

CD1d x Vdelta2 Gamma Delta bsTCE Antibody LAVA-051

LAVA 051

LAVA-051

LAVA051

---

Locations

United States, Georgia

United States, New York

United States, North Carolina

United States, Texas

Europe

Italy

Netherlands

Spain